FIGURE 1.

Flow chart of patient selection [1]. CARTITUDE‐1 inclusion criteria required at least three prior LOTs or double refractoriness to an immunomodulatory drug and a proteasome inhibitor; however, all enrolled patients received at least three prior LOTs [2]. CARTITUDE‐1 inclusion criterion was creatinine clearance of ≥40 mL/min/1.73 m²; however, all enrolled patients had creatine levels ≤ 2 mg/dL. Abbreviations: ECOG, Eastern Cooperative Oncology Group; LOT, line of therapy; MM, multiple myeloma; N _OBS, number of observations; RW, real world